Cohance Lifesciences Limited (BOM:543064)

Market Cap	349.17B
Revenue (ttm)	12.59B
Net Income (ttm)	2.41B
Shares Out	n/a
EPS (ttm)	9.40
PE Ratio	144.66
Forward PE	55.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,930
Average Volume	83,887
Open	911.05
Previous Close	914.15
Day's Range	896.70 - 932.65
52-Week Range	856.90 - 1,359.00
Beta	n/a
RSI	41.58
Earnings Date	Nov 7, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.